OBJECTIVES: To use restricted mean survival time, which summarizes treatment effects in terms of event-free time over a fixed time period, to evaluate the benefit of pravastatin therapy for primary prevention of cardiovascular disease in older adults. DESIGN: Secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialLipid-Lowering Trial (ALLHAT-LLT). SETTING: Ambulatory setting. PARTICIPANTS: Individuals aged 65 and older (mean aged 71, 49% female) free of cardiovascular disease (N=2,867). INTERVENTION: Pravastatin 40 mg/d (n=1,467) versus usual care (n=1,400). MEASUREMENTS: We estimated the difference in RMST for total and coronary heart disease (CHD)-free survival between the pravastatin and usual care groups over the 6-year trial period and used parametric survival models to estimate RMST differences projected over 10 years. RESULTS: Over 6 years, individuals treated with pravastatin lived (RMST 2,008.1 days), on average, 33.7 fewer days than those receiving usual care (RMST 2,041.8 days) (difference -33.7 days, 95% confidence interval (CI)=-67.0 to -0.5 days, p=.047). Pravastatin-treated individuals lived RMST 2,088.1 days), on average, 18.7 more days free of CHD over 6 years than those receiving usual care (RMST 2,069.4 days), but this difference was not statistically significant (difference 18.7 days, 95% CI=-10.4-47.8 days, p=.21). The 10-year projection showed that pravastatintreated individuals would live 108.1 fewer days (95% CI=-204.5 to -14.1, p=.03) than those receiving usual care, although treated individuals would gain 77.9 days (95% CI=3.8-159.6, p=.046) of CHD-free survival. CONCLUSION: RMST provides an intuitive and explicit way to express the effect of pravastatin therapy on CHDfree and overall survival in older adults free of cardiovascular disease. This measure allows a more personalized interpretation than hazard ratios of the benefits and risks of a medical intervention for decision-making.
I
nterpreting treatment effects reported from clinical trials is fundamental to shared decision-making about medical treatment in older adults, yet statistical measures routinely used in clinical trials, such as hazard ratios (HRs) and pvalues, provide little information about the clinical importance of treatment effect. Because p-values depend on the magnitude of treatment effect, as well as study size and event rates, small p-values may not indicate a clinically important treatment effect; likewise, nonsignificant p-values should perhaps not be interpreted as evidence for no treatment effect. [1] [2] [3] [4] Despite popular use, HRs, which represent the ratio of 2 hazard rates and are commonly estimated using Cox proportional hazards model, are not intuitive and are subject to misinterpretation. 5, 6 Without knowing the hazard in the control group, it is difficult to assess how a relative reduction in hazard due to the treatment translates into a clinically measurable benefit or harm. Interpretation becomes more difficult when the ratio of 2 hazards is not constant over the study period (changes over time).
An alternative way to summarize treatment effects is to compare median or mean survival time (time from baseline to event) of 2 treatment groups. Median survival time corresponds to time during follow-up at which half of the population has developed the event. Although intuitive, median survival time is insensitive to long-term survivors and may not be observed from data because of insufficient followup. Mean survival time difference can be interpreted as a gain or loss in average survival time due to the treatment, but mean survival time cannot be estimated in most clinical trials because of censoring (survival time is unknown for participants who do not experience the event by the end of study follow-up). Instead, restricted mean survival time (RMST) can be obtained by calculating mean survival time to end of follow-up or a clinically meaningful time point within the study duration. 7 Graphically, RMST corresponds to the area under the survival curve up to the time point. Difference in RMST is a useful measure of treatment effect that can be interpreted as a gain or loss in event-free survival time in the specified period due to the treatment. [5] [6] [7] [8] [9] [10] [11] [12] We demonstrate how RMST analysis enhances clinical interpretation of a clinical trial comparing pravastatin with usual care for primary prevention of coronary heart disease (CHD) in older populations. This topic is particularly relevant because the benefit of statins for primary prevention in older adults is controversial. [13] [14] [15] [16] In a recent post hoc analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid-Lowering Trial (ALLHAT-LLT) primary prevention cohort, 13 the risk of CHD was not statistically significantly lower in those randomized to pravastatin than in those receiving usual care (HR=0.81, 95% confidence interval (CI)=0.63-1.05, p=.12), although the risk of dying over 6 years was nonsignificantly greater (HR=1.18, 95% CI=0.97-1.42, p=.09). Although the authors concluded that "no benefit was found … for primary prevention … and a non-significant direction toward increased all-cause mortality was observed…," 13 the wide CI reflects a lack of precision and large uncertainty regarding the true benefit or harm of pravastatin. It does not exclude a possibility of benefit (up to 37% CHD reduction) or harm (up to 42% mortality increase) of pravastatin because of wide CIs of HRs, which depend on number of events. The clinical importance of such relative risk reduction or increase can be ambiguous to clinicians and patients. Therefore, we reanalyzed the ALLHAT-LLT data using RMST to enhance clinical interpretation of the effect of pravastatin therapy for primary prevention in older adults.
METHODS

Data Source
The ALLHAT-LLT was a randomized, open-label, controlled trial comparing pravastatin with usual care in adults with hypertension and additional CHD risk factors conducted between 1994 and 2002 in the United States. Details of study design and procedures are available elsewhere. 17 The ALLHAT-LLT primary prevention post hoc analysis included 2,867 adults aged 65 and older (mean age 71; 49% female; 90% taking antihypertensive medications; 51% with type 2 diabetes; mean low-density lipoprotein cholesterol 148 mg/dL) free of cardiovascular disease at baseline who were randomized to pravastatin 40 mg/d (n=1,467) or usual care (n=1,400). 13 The primary outcome was all-cause mortality and the secondary outcome was CHD events (fatal and nonfatal CHD). The mean follow-up duration (standard deviation) was 4.55 (1.60) years in the pravastatin group and 4.66 (1.58) years in the usual care group. 13 Because we reconstructed participant-level data from the published survival curves 18 to demonstrate RMST analysis, institutional review board approval was not necessary.
RMST Analysis
We calculated RMST from baseline to 6 years (end of study follow-up) in each treatment group for all-cause mortality and for CHD events, representing the average survival time and the average CHD-free survival time over 6 years. For each outcome, treatment effect was summarized by calculating RMST difference between the pravastatin and usual care groups at 6 years using the established estimation procedure. [6] [7] [8] We used the surv2sampleComp package in (R Foundation for Statistical Computing, Vienna, Austria) software to estimate RMST difference (R code and reconstructed datasets are provided in Supplementary Appendix S1). RMST difference is interpreted as number of event-free days gained or lost in the next 6 years due to pravastatin therapy relative to usual care. To estimate the long-term effect of pravastatin therapy, we fitted parametric Weibull survival models to estimate RMST difference at 10 years. All analyses were performed in R software version 3.4.
RESULTS
Over 6 years, individuals randomized to pravastatin lived, on average, 2,008.1 days; this was 33.7 days shorter (95% CI=-67.0 to -0.5, p=.047) than those receiving usual care, who lived, on average, 2,041.8 days (Table 1, Figure 1A ). The 95% CI suggests that the 6-year RMST difference could be as large as 67.0 days, which means that pravastatin-treated individuals might live 67 days less than those receiving usual care over 6 years. Six-year CHD-free mean survival time was 18.7 days longer (95% CI=-10.4-47.8) in those assigned to pravastatin (2,088.1 days) than in those receiving usual care (2,069.4 days), but this was not statistically significant (p=.21) (Table 1, Figure 1B) . Based on the 95% CI, pravastatin-treated individuals may live free of CHD events 10.4 days fewer to 47.8 days longer than those receiving usual care.
The 10-year RMST difference estimated from parametric models showed that pravastatin-treated individuals lived 108.1 days fewer (95% CI=-204.5 to -14.1) than those receiving usual care, although treated individuals gained 77.9 days (95% CI=3.8-159.6) of CHD-free survival (Table 1) .
DISCUSSION
The recent post hoc analysis of ALLHAT-LLT left several unanswered questions about the efficacy and safety of pravastatin therapy in older adults without cardiovascular disease. 13 Although the authors interpreted a HR of 0.81 (95% CI=0.63-1.05, p=.12) as evidence of no benefit of pravastatin therapy for primary prevention, the 95% CI included previously reported HRs in middle-aged 19 and older adults. 20 Conversely, the nonsignificant HR of 1.18
with a wide CI (95% CI=0.97-1.42, p=.09) for mortality suggests a lack of precision that does not exclude the possibility of harm from pravastatin therapy. Clinicians and patients may not be satisfied with this interpretation. 1 Estimated from parametric Weibull survival models fit based on reconstructed data. CHD = coronary heart disease. Figure 1 . Restricted mean survival time for (A) overall and (B) coronary heart disease-free survival over 6 years. Restricted mean survival time (RMST) represents mean event-free survival time from trial baseline to end (6 years), which is heuristically equivalent to the area under the Kaplan-Meier curve from the beginning of the curve to vertical dotted line. The difference in RMST between the 2 groups indicates the number of days gained or lost in terms of (A) overall and (B) coronary heart disease-free survival due to 6 years of pravastatin therapy compared with usual care.
RMST analysis is a useful approach that can improve clinical interpretability of HRs by placing the results on a time scale that can be understood intuitively. [5] [6] [7] [8] [9] [10] [11] [12] Our analysis of the ALLHAT-LLT primary prevention cohort using RMST showed that individuals treated with pravastatin could live free of CHD, on average, for an additional 18.7 days in 6 years, yet their overall survival was 33.7 days shorter than those who received usual care. Even if the cardiovascular benefit of pravastatin was projected to 10 years, the average gain in CHD-free survival was 77.9 days, as opposed to an average loss of 108.1 days in overall survival. These results provide strong evidence that pravastatin therapy for primary prevention in older adults is unlikely to provide a clinically important survival benefit over 6 or 10 years. Our results also suggest that individuals with a remaining life expectancy of 10 years may gain CHD-free survival from pravastatin therapy, despite a reduction in overall survival; the clinical meaning of the magnitude of treatment effect and trade-off between CHD-free and overall survival will depend on one's personal values. As such, summarizing treatment effect in terms of number of eventfree days within a prespecified time frame offers a more explicit way than hazard ratios to interpret the risks and benefits of a treatment.
In addition to interpretability, RMST analysis has methodological advantages over HRs. In Cox proportional hazards models, 21 which are widely used to estimate HRs, a core assumption is that the ratio of the hazard rate in the treatment group to that in the control group is constant throughout study follow-up (proportional hazards assumption). Violation of this assumption is common. Evidence of nonproportionality was observed in 24% of 54 cancer clinical trials. 22 In the ALLHAT-LLT post hoc analysis, the cumulative incidence curves for CHD crossed between the 2 groups ( Figure 2 in the published paper 13 ), indicating nonproportionality. When this assumption is breached, a single HR is no longer an informative summary of treatment effect. 23 In contrast to calculating HRs, calculating a RMST difference does not require any model assumption. When the hazards are not proportional, RMST analysis has more statistical power, resulting in more-precise estimates. [6] [7] [8] 11 One thing to be careful of with RMST analysis is that the time frame to compute RMST should be chosen a priori, at the design stage of a clinical trial, such that it represents a clinically meaningful time frame to evaluate the treatment benefit. In post hoc analysis, the end of trial follow-up can be used, as we did in the ALLHAT-LLT analysis. A long-term projection beyond trial duration is possible by fitting a parametric survival model, assuming that the parametric model provides a good approximation.
Because clinicians are encouraged to engage in shared decision-making conversations with patients regarding use of statins for primary prevention, 24 clear communication of the benefit and risk is critical. HRs tend to exaggerate treatment effect and may misinform treatment decisions, which can be mitigated by presenting absolute rates. 22, 25 Some may be concerned that RMST differences tend to understate treatment effects when the majority of patients do not experience the event. The best way to present the evidence for clinical decision-making remains to be determined. To individualize drug therapy in older adults, it is recommended that the time to benefit from a treatment be compared with the person's life expectancy, 26 but time to benefit is not readily estimated from clinical trials and, even if estimated, is often too uncertain to guide clinical decisions. 27 RMST analysis that quantifies treatment effect within a prespecified, clinically relevant time frame (e.g., 5 years for individuals with intermediate prognosis and 10 years for those with good prognosis) can be a useful alternative to the time-to-benefit estimation.
Our results need to be interpreted within the context of limitations of the original ALLHAT-LLT. Analysis of the primary prevention cohort was not specified a priori. Openlabel design might have resulted in different changes in lifestyle factors and high rates of crossover (22-29%) between the two arms, 13 which may explain the modest CHD reduction with pravastatin during the study period. We did not examine subgroups that might have had a greater RMST gain, which should be investigated in future research.
In conclusion, RMST provides an intuitive, explicit way to express the effect of pravastatin on CHD-free and overall survival for primary prevention in older adults. RMST allows a more personalized interpretation of the benefits and risks of treatment than HRs. Because RMST is intuitively interpreted and conveniently estimated using standard statistical software, we recommend that it be routinely reported in conjunction with HRs and absolute rates in clinical studies evaluating medical interventions. Future research is warranted to investigate how RMST can improve communication between clinicians and patients and influence treatment choices.
